Grossman - Figure 13
The overall survival results for definitive therapy from BA06 30894
FIG. 13: This Figure shows the overall survival results for definitive therapy from BA06 30894.[4] Overall survival was better in the patients who received neoadjuvant chemotherapy and radiotherapy vs radiotherapy alone (upper left) and in the patients who receiving neoadjuvant chemotherapy and cystectomy vs cystectomy alone (upper right). Locoregional disease-free survival did not different between patients receiving radiotherapy alone or with neoadjuvant therapy (lower left), but appeared better for patients who underwent cystectomy alone compared with those randomized to cystectomy plus neoadjuvant chemotherapy (lower right).
References
International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group; Griffiths G, Hall R, Sylvester R, et al. International Phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29:2171−7 https://doi.org/10.1200/JCO.2010.32.3139
